Join to View Full Profile
1 Medical Center DrSection of Clinical Pharmacology DHMCLebanon, NH 03756
Phone+1 603-650-5000
Are you Dr. Lewis?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 16 invites waiting! - Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Lionel Lewis, MD is an internist in Lebanon, New Hampshire. He is currently licensed to practice medicine in New Hampshire. He is affiliated with Dartmouth-Hitchcock Medical Center and is a Professor at Geisel School of Medicine.
Education & Training
The University of Wales College of MedicineClass of 1988
Certifications & Licensure
NH State Medical License 1993 - 2025
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
- Docetaxel in Treating Patients With Solid Tumors Start of enrollment: 1998 Sep 01
- Adenosine Triphosphate in Treating Patients With Advanced Solid Tumors Start of enrollment: 2000 Oct 01
- Temozolomide Plus PEG-Interferon Alfa-2B in Treating Patients With Advanced Solid Tumors Start of enrollment: 2000 Oct 01
- Join now to see all
Publications & Presentations
PubMed
- Space travel-associated motion sickness and its treatment.Jay C Buckey, Mimi Lan, Lionel D Lewis
British Journal of Clinical Pharmacology. 2025-04-04 - Phase II trial of blood-brain barrier permeable peptide-paclitaxel conjugate ANG1005 in patients with recurrent high-grade glioma.Crismita Dmello, Andrew Brenner, David Piccioni, Patrick Y Wen, Jan Drappatz
Neuro-Oncology Advances. 2024-12-14 - Implementation of a pharmacist-guided pharmacogenomics dosing service at a rural NCI-designated comprehensive cancer center.Jenna K Green, Laura J Hackett, Donald C Green, Sophie J Deharvengt, Gabriel A Brooks
Journal of Oncology Pharmacy Practice. 2024-09-04
Press Mentions
Issue HighlightsAugust 24th, 2020
Drug Combination More Effective in Metastatic Renal Cell CancerJuly 26th, 2017
Grant Support
- 7HP349, an Integrin Activator to Treat Patients With anti-PD-1 Resistant Solid Tumors7 HILLS PHARMA, LLC2023–2025
- Protocol Review And Monitoring SystemNational Cancer Institute2009–2012
- Clinical Pharmacology Shared ResourceNational Cancer Institute2009–2012
- Toxicology, Pathology And Biodistribution Core (Tpb Core)National Cancer Institute2011
- Clinical MolecularNational Cancer Institute2004–2008
